Drug Trial Radar · NCT01474161
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505
Last checked: Nov 19, 2026Latest source record: Nov 27, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
96
Actual
Start
Nov 2011
Primary completion
Nov 2012
Study completion Nov 2012
Sponsor
- Lead sponsor
- GenfitIndustry
- Sponsor type
- Industry
- Collaborators
- SGS Aster S.A.S.; Naturalpha
- First posted
- Nov 18, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60 mg GFT505) and the old GFT505 formulation (capsule dosed at 20 mg GFT505) in healthy male subjects and to assess the impact of gender on this relative bioavailability after administration in male and female subjects. Using the new formulation, a single and a multiple ascending dose study will be performed in overweight or obese male subjects otherwise healthy whose demographic and physiological characteristics are thought to be closer to those of the target population (Type 2 diabetes). Thereafter, a group of male and female patients with Type 2 diabetes will receive multiple dose administration of GFT505.
Conditions
- Type 2 Diabetes
- Diabetes Mellitus, Type 2
- Metabolic Diseases
- Cardiovascular Diseases
- Obese
- Dyslipidemia
Interventions
GFT505 120mg - old formulationDrug
hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.
GFT505 120mg - new formulationDrug
hard gelatin capsules dosed at 60mg, one single oral administration (Study Part I) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 2 capsules with 250mL of water.
GFT505 180mg - new formulationDrug
hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.
GFT505 240mg - new formulationDrug
hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.
GFT505 300mg - new formulationDrug
hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II), 5 capsules with 250mL of water.
PlaceboDrug
hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics parameters (Study Part I)Time frame: 24h post-dose
- Safety parameters (Study Parts II, III and IV)Time frame: Part II : 5 days ; Part III : 20 days ; Part IV : 20 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SGS Aster S.A.S. - Phase I Clinical Unit
Paris, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.